These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15330221)

  • 1. Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder.
    Oldham JM; Bender DS; Skodol AE; Dyck IR; Sanislow CA; Yen S; Grilo CM; Shea MT; Zanarini MC; Gunderson EJ; McGlashan TH
    J Psychiatr Pract; 2004 May; 10(3):156-61. PubMed ID: 15330221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services.
    Paton C; Crawford MJ; Bhatti SF; Patel MX; Barnes TR
    J Clin Psychiatry; 2015 Apr; 76(4):e512-8. PubMed ID: 25919844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines.
    Riffer F; Farkas M; Streibl L; Kaiser E; Sprung M
    Int J Psychiatry Clin Pract; 2019 Sep; 23(3):178-188. PubMed ID: 31140337
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose.
    Bellino S; Rinaldi C; Bozzatello P; Bogetto F
    Curr Med Chem; 2011; 18(22):3322-9. PubMed ID: 21728970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management and effectiveness of psychopharmacology in emotionally unstable and borderline personality disorder.
    Silk KR
    J Clin Psychiatry; 2015 Apr; 76(4):e524-5. PubMed ID: 25919848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why patients with severe personality disorders are overmedicated.
    Paris J
    J Clin Psychiatry; 2015 Apr; 76(4):e521. PubMed ID: 25919846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains.
    Ingenhoven TJ; Duivenvoorden HJ
    J Clin Psychopharmacol; 2011 Aug; 31(4):489-96. PubMed ID: 21694626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy.
    Paolini E; Mezzetti FA; Pierri F; Moretti P
    Int J Psychiatry Clin Pract; 2017 Mar; 21(1):75-79. PubMed ID: 27669762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials.
    Vita A; De Peri L; Sacchetti E
    J Clin Psychopharmacol; 2011 Oct; 31(5):613-24. PubMed ID: 21869691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for borderline patients: business as usual or by default?
    Ingenhoven T
    J Clin Psychiatry; 2015 Apr; 76(4):e522-3. PubMed ID: 25919847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mental health service utilization among borderline personality disorder patients inpatient].
    Cailhol L; Thalamas C; Garrido C; Birmes P; Lapeyre-Mestre M
    Encephale; 2015 Apr; 41(2):115-22. PubMed ID: 25526809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of UK and US guidelines for drug treatment in borderline personality disorder.
    Tyrer P; Silk KR
    Int Rev Psychiatry; 2011 Aug; 23(4):388-94. PubMed ID: 22026496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting.
    Magni LR; Ferrari C; Barlati S; Ridolfi ME; Prunetti E; Vanni G; Bateni M; Diaferia G; Macis A; Meloni S; Perna G; Occhialini G; Vita A; Rossi G; Rossi R
    Psychiatry Res; 2021 Jan; 295():113556. PubMed ID: 33189367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine trial in borderline personality disorder.
    Cornelius JR; Soloff PH; Perel JM; Ulrich RF
    Psychopharmacol Bull; 1990; 26(1):151-4. PubMed ID: 2371370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication for borderline personality disorder: a survey at a secure hospital.
    Haw C; Stubbs J
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):280-5. PubMed ID: 22122000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices.
    Knappich M; Hörz-Sagstetter S; Schwerthöffer D; Leucht S; Rentrop M
    Int Clin Psychopharmacol; 2014 Jul; 29(4):224-8. PubMed ID: 24896541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication utilization patterns and methods of suicidality in borderline personality disorder.
    Makela EH; Moeller KE; Fullen JE; Gunel E
    Ann Pharmacother; 2006 Jan; 40(1):49-52. PubMed ID: 16303987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary trial of fluoxetine in refractory borderline patients.
    Cornelius JR; Soloff PH; Perel JM; Ulrich RF
    J Clin Psychopharmacol; 1991 Apr; 11(2):116-20. PubMed ID: 2056138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative Deprescribing in Borderline Personality Disorder: A Narrative Review.
    Fineberg SK; Gupta S; Leavitt J
    Harv Rev Psychiatry; 2019; 27(2):75-86. PubMed ID: 30676404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychopharmacology of borderline personality disorder: a review.
    Cowdry RW
    J Clin Psychiatry; 1987 Aug; 48 Suppl():15-25. PubMed ID: 2886493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.